A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide

The standard‐of‐care for patients with acute promyelocytic leukemia (APL) relapsing after upfront arsenic trioxide (ATO) therapy is not defined. The present study was undertaken to evaluate the safety of addition of bortezomib to ATO in the treatment of relapsed APL based on our previously reported...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Uday, Ganesan, Saravanan, Alex, Ansu Abu, Palani, Hamenth, David, Sachin, Balasundaram, Nithya, Venkatraman, Arvind, Thenmozhi, Mani, Jeyaseelan, Lakshmanan, Korula, Anu, Devasia, Anup, Abraham, Aby, Janet, Nancy Beryl, Balasubramanian, Poonkuzhali, George, Biju, Mathews, Vikram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163093/
https://www.ncbi.nlm.nih.gov/pubmed/32059085
http://dx.doi.org/10.1002/cam4.2883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163093/
https://www.ncbi.nlm.nih.gov/pubmed/32059085
http://dx.doi.org/10.1002/cam4.2883

Ejemplares similares